Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

Js Smolen*, P Emery, Gianfranco Ferraccioli, W Samborski, F Berenbaum, Or Davies, W Koetse, O Purcaru, B Bennett, H. Burkhardt

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo

68 Citazioni (Scopus)

Abstract

This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.
Lingua originaleInglese
pagine (da-a)843-850
Numero di pagine8
RivistaAnnals of the Rheumatic Diseases
Volume74
Numero di pubblicazione5
DOI
Stato di pubblicazionePubblicato - 2015
Pubblicato esternamente

All Science Journal Classification (ASJC) codes

  • Reumatologia
  • Immunologia e Allergia
  • Immunologia
  • Biochimica, Genetica, Biologia Molecolare Generali

Keywords

  • Adolescent
  • Anti-TNF
  • Antibodies
  • Antirheumatic Agents
  • Arthritis
  • Certolizumab Pegol
  • Combination
  • DMARDs (biologic)
  • Disease Activity
  • Double-Blind Method
  • Drug Therapy
  • Humanized
  • Immunoglobulin Fab Fragments
  • Immunosuppressive Agents
  • Maintenance Chemotherapy
  • Methotrexate
  • Middle Aged
  • Monoclonal
  • Polyethylene Glycols
  • Remission Induction
  • Rheumatoid
  • Rheumatoid Arthritis
  • Severity of Illness Index
  • Treatment Outcome
  • Young Adult

Fingerprint

Entra nei temi di ricerca di 'Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial'. Insieme formano una fingerprint unica.

Cita questo